Pharmacokinetics of clavulanic acid-potentiated ticarcillin in renal failure. 1987

I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton

The serum kinetics of an intravenous bolus of a combination of ticarcillin (TIC) (3 g) and clavulanic acid (CLAV) (0.2 g) have been determined in a number of patients with different degrees of renal failure as characterized by creatinine clearance. The volume of distribution for both drugs was unaffected by renal failure. Indices of serum and renal drug clearance were related to the degree of renal failure. TIC was cleared more slowly than CLAV. Anephric patients may have a higher serum clearance of CLAV than patients categorized by creatinine clearance as having severe renal failure; this could be due to an increase in metabolic clearance. Haemodialysis effectively clears both drugs. "Rebound" serum concentrations were consistently observed for TIC, but were observed in only one patient for CLAV. Continuous ambulatory peritoneal dialysis results in significant recovery of both drugs. The dosing requirements for the combination of TIC and CLAV in patients with renal failure are considered.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D002969 Clavulanic Acids Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects. Acids, Clavulanic
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses

Related Publications

I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
May 1986, The Journal of antimicrobial chemotherapy,
I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
May 1986, The Journal of antimicrobial chemotherapy,
I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
December 1986, Antimicrobial agents and chemotherapy,
I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
May 1986, The Journal of antimicrobial chemotherapy,
I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
March 1986, International journal of clinical pharmacology, therapy, and toxicology,
I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
September 1994, Antimicrobial agents and chemotherapy,
I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
December 1985, The Journal of antimicrobial chemotherapy,
I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
June 1983, Antimicrobial agents and chemotherapy,
I D Watson, and M Boulton-Jones, and M J Stewart, and I Henderson, and C D Payton
August 1985, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!